TScan Therapeutics, Inc.
NASDAQ: TCRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gavin MacBeath
- Employees
- 143
- Headquarters
- Waltham, United States
- IPO year
- 2021
- Market cap
- $53.8M
- Website
- https://www.tscan.com
Loading TCRX…
Loading profile data…Frequently asked questions about TCRX
What does TScan Therapeutics, Inc. (TCRX) do?
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblas...
Where does TCRX trade?
TScan Therapeutics, Inc. (TCRX) trades on the NASDAQ.
What sector is TCRX in?
TScan Therapeutics, Inc. (TCRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of TScan Therapeutics, Inc.?
Gavin MacBeath is the chief executive officer of TScan Therapeutics, Inc. (TCRX).
Where is TScan Therapeutics, Inc. headquartered?
TScan Therapeutics, Inc. is headquartered in United States.
Does TCRX pay a dividend?
TScan Therapeutics, Inc. (TCRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TCRX go public?
TScan Therapeutics, Inc. (TCRX) completed its initial public offering in 2021.